Laboratory Management
Please note:
Adobe PDF Reader is required to view clinical guideline documents.
There may be instances in which your health plan policies take precedence over the EviCore by Evernorth clinical guidelines. If you have any questions, please reach out to your health plan.
Follow the below steps to access the clinical guidelines.
- Enter your Health Plan name into the search field and click on the magnifying glass.
- To access the guideline specific to your request, locate the guideline that the decision was based on from within your letter.
- Identify the guideline title and then search for that guideline title by scrolling down on the page or entering the guideline title into the guideline title search field.
- Open the guideline document.
Example:
The statement in your letter reads:
We based this decision on the guideline as listed below:
-MTHFR Variant Analysis for Hyperhomocysteinemia (MOL.TX.205).
Enter your Health Plan name into the search field and click on the magnifying glass.
Enter the guideline title into the search field for the guideline name.
Once the search results appear, click on the guideline to open it.
If you require a copy of the guidelines that were used to make a determination on a specific request of treatment or services, please email the case number and request to: reqcriteria@EviCore.com.
To request any additional assistance in accessing the guidelines, provide feedback or clinical evidence related to the evidence-based guidelines, please click here.
EviCore coverage policies include background and supporting information and citations for sources used to develop the policy. Some clinical policies may have a supplemental literature summary available which will provide additional commentary regarding clinical benefits and harms to the patient population being served. Additional literature summaries may be accessed by selecting ‘Supplemental Information’ and then entering “EviCore by Evernorth” in the search by health plan function.
Code Lists
Guidelines
-
MOL.AD.107.A: Unique Test Identifiers for Non-Specific Procedure Codes
-
MOL.AD.304.A: Medical Necessity Review Information Requirements
-
MOL.AD.314.A: Date of Service and Authorization Period Effective Date
-
MOL.AD.364.A: Special Circumstances Influencing Coverage Determinations
-
MOL.AD.411.A: Laboratory Testing Procedure Code Requirements
-
MOL.AD.412.A: Laboratory Billing and Reimbursement
-
MOL.CU.109.A: Genetic Testing for Cancer Susceptibility and Hereditary Cancer Syndromes
-
MOL.CU.110.A: Genetic Testing for Carrier Status
-
MOL.CU.111.A: Genetic Testing for Non-Medical Purposes
-
MOL.CU.112.A: Genetic Testing for Prenatal Screening and Diagnostic Testing
-
MOL.CU.113.A: Genetic Testing for the Screening, Diagnosis, and Monitoring of Cancer
-
MOL.CU.114.A: Genetic Testing to Diagnose Non-Cancer Conditions
-
MOL.CU.115.A: Genetic Testing to Predict Disease Risk
-
MOL.CU.116.A: Genetic Testing by Multigene Panels
-
MOL.CU.117.A: Experimental, Investigational, or Unproven Laboratory Testing
-
MOL.CU.118.A: Pharmacogenomic Testing for Drug Toxicity and Response
-
MOL.CU.119.A: Preimplantation Genetic Screening and Diagnosis
-
MOL.CU.246.A: Hereditary (Germline) Testing After Tumor (Somatic) Testing
-
MOL.CU.256.A: Confirmatory Genetic Testing
-
MOL.CU.291.A: Genetic Testing for Known Familial Mutations
-
MOL.CU.292.A: Genetic Testing for Variants of Uncertain Clinical Significance
-
MOL.CU.333.B: Medically Necessary Laboratory Testing
-
MOL.TS.120.A: 4Kscore for Prostate Cancer Risk Assessment
-
MOL.TS.122.A: Afirma Thyroid Cancer Classifier Tests
-
MOL.TS.123.A: AlloMap Gene Expression Profiling For Heart Transplant Rejection
-
MOL.TS.124.A: Alpha-1 Antitrypsin Deficiency Testing
-
MOL.TS.125.A: Amyotrophic Lateral Sclerosis (ALS) Genetic Testing
-
MOL.TS.126.A: Angelman Syndrome Genetic Testing
-
MOL.TS.128.A: APOE Variant Analysis for Alzheimer Disease Testing
-
MOL.TS.129.A: Ashkenazi Jewish Carrier Screening
-
MOL.TS.144.A: CADASIL Genetic Testing
-
MOL.TS.148.A: Charcot-Marie-Tooth Neuropathy Genetic Testing
-
MOL.TS.150.A: Chromosomal Microarray Testing For Developmental Disorders (Prenatal and Postnatal)
-
MOL.TS.151.A: Chromosome Analysis for Blood and Bone Marrow Cancers
-
MOL.TS.152.A: Cologuard Screening for Colorectal Cancer
-
MOL.TS.153.A: ConfirmMDx for Prostate Cancer Risk Assessment
-
MOL.TS.158.A: Cystic Fibrosis Genetic Testing
-
MOL.TS.161.A: Duchenne and Becker Muscular Dystrophy Testing
-
MOL.TS.162.A: Early Onset Familial Alzheimer Disease Genetic Testing
-
MOL.TS.164.A: SEPT9 Methylation Analysis for Colorectal Cancer
-
MOL.TS.165.A: Carrier Screening Panels, Including Targeted, Pan-Ethnic, Universal, and Expanded
-
MOL.TS.168.A: Familial Adenomatous Polyposis Genetic Testing
-
MOL.TS.169.A: Familial Hypercholesterolemia Genetic Testing
-
MOL.TS.170.A: Familial Malignant Melanoma Genetic Testing
-
MOL.TS.172.A: FMR1-Related Disorders (Fragile X) Genetic Testing
-
MOL.TS.182.A: Hereditary Cancer Syndrome Multigene Panels
-
MOL.TS.183.A: HFE Hemochromatosis Genetic Testing
-
MOL.TS.188.A: Huntington Disease Genetic Testing
-
MOL.TS.193.A: Li-Fraumeni Syndrome Genetic Testing
-
MOL.TS.194.A: Liquid Biopsy Testing
-
MOL.TS.197.A: Lynch Syndrome Genetic Testing
-
MOL.TS.199.A: Lynch Syndrome Tumor Screening - Second-Tier
-
MOL.TS.200.A: Mammaprint 70-Gene Breast Cancer Recurrence Assay
-
MOL.TS.206.A: MUTYH Associated Polyposis Genetic Testing
-
MOL.TS.209.A: Non-Invasive Prenatal Screening
-
MOL.TS.211.A: Oncotype DX for Breast Cancer Prognosis
-
MOL.TS.213.A: Oncotype DX for Colorectal Cancer Recurrence Risk
-
MOL.TS.215.A: PCA3 Testing for Prostate Cancer
-
MOL.TS.216.A: Peutz-Jeghers Syndrome Genetic Testing
-
MOL.TS.217.A: Prader-Willi Syndrome Genetic Testing
-
MOL.TS.220.A: Prenatal Maternal Serum Screening
-
MOL.TS.222.A: Prosigna Breast Cancer Prognostic Gene Signature Assay
-
MOL.TS.223.A: PTEN Hamartoma Tumor Syndromes Genetic Testing
-
MOL.TS.224.A: Rett Syndrome Genetic Testing
-
MOL.TS.225.A: Spinal Muscular Atrophy Genetic Testing
-
MOL.TS.228.A: Tissue of Origin Testing for Cancer of Unknown Primary
-
MOL.TS.230.A: Somatic Mutation Testing
-
MOL.TS.233.A: Von Hippel-Lindau Disease Genetic Testing
-
MOL.TS.234.A: EndoPredict for Breast Cancer Prognosis
-
MOL.TS.235.A: Exome Sequencing
-
MOL.TS.236.A: Cxbladder
-
MOL.TS.238.A: BRCA Analysis
-
MOL.TS.240.A: BCR-ABL Negative Myeloproliferative Neoplasm Genetic Testing
-
MOL.TS.248.A: Breast Cancer Index for Breast Cancer Prognosis
-
MOL.TS.250.A: NETest
-
MOL.TS.251.A: PALB2 Genetic Testing for Cancer Risk
-
MOL.TS.254.A: DecisionDX Uveal Melanoma
-
MOL.TS.255.A: Oncotype DX Breast DCIS
-
MOL.TS.257.A: Epilepsy Genetic Testing
-
MOL.TS.258.A: Maturity-Onset Diabetes of the Young Genetic Testing
-
MOL.TS.259.A: ThyGeNEXT and ThyraMIR miRNA Gene Expression Classifier
-
MOL.TS.264.A: SelectMDx
-
MOL.TS.266.A: Mitochondrial Disorders Genetic Testing
-
MOL.TS.269.A: Autism, Intellectual Disability, and Developmental Delay Genetic Testing
-
MOL.TS.270.A: Thyroseq
-
MOL.TS.273.A: Nonsyndromic Hearing Loss and Deafness Genetic Testing
-
MOL.TS.276.A: Polymerase Gamma (POLG) Related Disorders Genetic Testing
-
MOL.TS.282.A: DermTech Melanoma Test
-
MOL.TS.285.A: Multiple Endocrine Neoplasia Type 1 Genetic Testing
-
MOL.TS.286.A: Multiple Endocrine Neoplasia Type 2 Genetic Testing
-
MOL.TS.287.A: Hereditary Pancreatitis Genetic Testing
-
MOL.TS.288.A: Limb-Girdle Muscular Dystrophy Genetic Testing
-
MOL.TS.290.A: Facioscapulohumeral Muscular Dystrophy Genetic Testing
-
MOL.TS.294.A: Decipher Prostate Cancer Classifier
-
MOL.TS.295.A: Genomic Prostate Score
-
MOL.TS.297.A: Prolaris
-
MOL.TS.301.A: Neurofibromatosis Type 1 Genetic Testing
-
MOL.TS.302.A: Legius Syndrome Genetic Testing
-
MOL.TS.306.A: Genome Sequencing
-
MOL.TS.307.A: AlloSure for Kidney Transplant Rejection
-
MOL.TS.308.A: Hemoglobinopathies Genetic Testing
-
MOL.TS.312.A: Myotonic Dystrophy Type 1 Genetic Testing
-
MOL.TS.324.A: CHARGE Syndrome and CHD7 Disorder Genetic Testing
-
MOL.TS.344.A: Chromosomal Microarray for Solid Tumors
-
MOL.TS.356.A: Microsatellite Instability and Immunohistochemistry Testing in Cancer
-
MOL.TS.359.A: Inflammatory Bowel Disease Biomarker Testing
-
MOL.TS.360.A: Inherited Bone Marrow Failure Syndrome (IBMFS) Testing
-
MOL.TS.361.A: Human Platelet and Red Blood Cell Antigen Genotyping
-
MOL.TS.366.A: OvaSuite
-
MOL.TS.370.A: Inherited Thrombophilia Genetic Testing
-
MOL.TS.371.A: Noonan Spectrum Disorder Genetic Testing
-
MOL.TS.396.A: Multi-Cancer Early Detection Screening
-
MOL.TS.401.A: Liver Fibrosis Assessment Biomarkers
-
MOL.TS.410.A: Cardiomyopathy and Arrhythmia Genetic Testing
-
MOL.TS.413.A: ColoSense for Colorectal Cancer
-
MOL.TS.419.A: Primary Ciliary Dyskinesia Genetic Testing
-
MOL.TS.425.A: Hereditary Ataxia Genetic Testing
-
MOL.TS.427.A: Hereditary Connective Tissue and Thoracic Aortic Disease Genetic Testing
Guidelines
-
MOL.AD.107.A: Unique Test Identifiers for Non-Specific Procedure CodesEffective 11/01/2025 - 12/31/2025
-
MOL.AD.304.A: Medical Necessity Review Information RequirementsEffective 11/01/2025 - 12/31/2025
-
MOL.AD.314.A: Date of Service and Authorization Period Effective DateEffective 11/01/2025 - 12/31/2025
-
MOL.AD.364.A: Special Circumstances Influencing Coverage DeterminationsEffective 11/01/2025 - 12/31/2025
-
MOL.AD.411.A: Laboratory Testing Procedure Code RequirementsEffective 11/01/2025 - 12/31/2025
-
MOL.AD.412.A: Laboratory Billing and ReimbursementEffective 11/01/2025 - 12/31/2025
-
MOL.CU.109.A: Genetic Testing for Cancer Susceptibility and Hereditary Cancer SyndromesEffective 11/01/2025 - 12/31/2025
-
MOL.CU.110.A: Genetic Testing for Carrier StatusEffective 11/01/2025 - 12/31/2025
-
MOL.CU.111.A: Genetic Testing for Non-Medical PurposesEffective 11/01/2025 - 12/31/2025
-
MOL.CU.112.A: Genetic Testing for Prenatal Screening and Diagnostic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.CU.113.A: Genetic Testing for the Screening, Diagnosis, and Monitoring of CancerEffective 11/01/2025 - 12/31/2025
-
MOL.CU.114.A: Genetic Testing to Diagnose Non-Cancer ConditionsEffective 11/01/2025 - 12/31/2025
-
MOL.CU.115.A: Genetic Testing to Predict Disease RiskEffective 11/01/2025 - 12/31/2025
-
MOL.CU.116.A: Genetic Testing by Multigene PanelsEffective 11/01/2025 - 12/31/2025
-
MOL.CU.117.A: Experimental, Investigational, or Unproven Laboratory TestingEffective 11/01/2025 - 12/31/2025
-
MOL.CU.118.A: Pharmacogenomic Testing for Drug Toxicity and ResponseEffective 11/01/2025 - 12/31/2025
-
MOL.CU.119.A: Preimplantation Genetic Screening and DiagnosisEffective 11/01/2025 - 12/31/2025
-
MOL.CU.246.A: Hereditary (Germline) Testing After Tumor (Somatic) TestingEffective 11/01/2025 - 12/31/2025
-
MOL.CU.256.A: Confirmatory Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.CU.291.A: Genetic Testing for Known Familial MutationsEffective 11/01/2025 - 12/31/2025
-
MOL.CU.292.A: Genetic Testing for Variants of Uncertain Clinical SignificanceEffective 11/01/2025 - 12/31/2025
-
MOL.CU.333.B: Medically Necessary Laboratory TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.120.A: 4Kscore for Prostate Cancer Risk AssessmentEffective 11/01/2025 - 12/31/2025
-
MOL.TS.122.A: Afirma Thyroid Cancer Classifier TestsEffective 11/01/2025 - 12/31/2025
-
MOL.TS.123.A: AlloMap Gene Expression Profiling For Heart Transplant RejectionEffective 11/01/2025 - 12/31/2025
-
MOL.TS.124.A: Alpha-1 Antitrypsin Deficiency TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.125.A: Amyotrophic Lateral Sclerosis (ALS) Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.126.A: Angelman Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.128.A: APOE Variant Analysis for Alzheimer Disease TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.129.A: Ashkenazi Jewish Carrier ScreeningEffective 11/01/2025 - 12/31/2025
-
MOL.TS.130.A: Ataxia-Telangiectasia Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.144.A: CADASIL Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.148.A: Charcot-Marie-Tooth Neuropathy Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.150.A: Chromosomal Microarray Testing for Developmental Disorders (Prenatal and Postnatal)Effective 11/01/2025 - 12/31/2025
-
MOL.TS.151.A: Chromosome Analysis for Blood and Bone Marrow CancersEffective 11/01/2025 - 12/31/2025
-
MOL.TS.152.A: Cologuard Screening for Colorectal CancerEffective 11/01/2025 - 12/31/2025
-
MOL.TS.153.A: ConfirmMDx for Prostate Cancer Risk AssessmentEffective 11/01/2025 - 12/31/2025
-
MOL.TS.158.A: Cystic Fibrosis Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.159.A: Dentatorubral-Pallidoluysian Atrophy Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.161.A: Duchenne and Becker Muscular Dystrophy TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.162.A: Early Onset Familial Alzheimer Disease Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.164.A: SEPT9 Methylation Analysis for Colorectal CancerEffective 11/01/2025 - 12/31/2025
-
MOL.TS.165.A: Carrier Screening Panels, Including Targeted, Pan-Ethnic, Universal, and ExpandedEffective 11/01/2025 - 12/31/2025
-
MOL.TS.168.A: Familial Adenomatous Polyposis Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.169.A: Familial Hypercholesterolemia Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.170.A: Familial Malignant Melanoma Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.172.A: FMR1-Related Disorders (Fragile X) Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.182.A: Hereditary Cancer Syndrome Multigene PanelsEffective 11/01/2025 - 12/31/2025
-
MOL.TS.183.A: HFE Hemochromatosis Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.188.A: Huntington Disease Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.193.A: Li-Fraumeni Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.194.A: Liquid Biopsy TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.197.A: Lynch Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.199.A: Lynch Syndrome Tumor Screening - Second TierEffective 11/01/2025 - 12/31/2025
-
MOL.TS.200.A: Mammaprint 70-Gene Breast Cancer Recurrence AssayEffective 11/01/2025 - 12/31/2025
-
MOL.TS.202.A: Marfan Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.206.A: MUTYH Associated Polyposis Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.209.A: Non-Invasive Prenatal ScreeningEffective 11/01/2025 - 12/31/2025
-
MOL.TS.211.A: Oncotype DX for Breast Cancer PrognosisEffective 11/01/2025 - 12/31/2025
-
MOL.TS.213.A: Oncotype DX for Colorectal Cancer Recurrence RiskEffective 11/01/2025 - 12/31/2025
-
MOL.TS.215.A: PCA3 Testing for Prostate CancerEffective 11/01/2025 - 12/31/2025
-
MOL.TS.216.A: Peutz-Jeghers Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.217.A: Prader-Willi Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.220.A: Prenatal Maternal Serum ScreeningEffective 11/01/2025 - 12/31/2025
-
MOL.TS.222.A: Prosigna Breast Cancer Prognostic Gene Signature AssayEffective 11/01/2025 - 12/31/2025
-
MOL.TS.223.A: PTEN Hamartoma Tumor Syndromes Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.224.A: Rett Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.225.A: Spinal Muscular Atrophy Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.227.A: Thoracic Aortic Aneurysms and Dissections (TAAD) Panel Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.228.A: Tissue of Origin Testing for Cancer of Unknown PrimaryEffective 11/01/2025 - 12/31/2025
-
MOL.TS.230.A: Somatic Mutation TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.232.A: VeriStrat Testing for NSCLC TKI ResponseEffective 11/01/2025 - 12/31/2025
-
MOL.TS.233.A: Von Hippel-Lindau Disease Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.234.A: EndoPredict for Breast Cancer PrognosisEffective 11/01/2025 - 12/31/2025
-
MOL.TS.235.A: Exome SequencingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.236.A: CxbladderEffective 11/01/2025 - 12/31/2025
-
MOL.TS.238.A: BRCA AnalysisEffective 11/01/2025 - 12/31/2025
-
MOL.TS.240.A: BCR-ABL Negative Myeloproliferative Neoplasm TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.248.A: Breast Cancer Index for Breast Cancer PrognosisEffective 11/01/2025 - 12/31/2025
-
MOL.TS.250.A: NETestEffective 11/01/2025 - 12/31/2025
-
MOL.TS.251.A: PALB2 Genetic Testing for Cancer RiskEffective 11/01/2025 - 12/31/2025
-
MOL.TS.254.A: DecisionDX Uveal MelanomaEffective 11/01/2025 - 12/31/2025
-
MOL.TS.255.A: Oncotype DX Breast DCISEffective 11/01/2025 - 12/31/2025
-
MOL.TS.257.A: Epilepsy Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.258.A: Maturity-Onset Diabetes of the Young (MODY) Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.259.A: ThyGeNEXT and ThyraMIR miRNA Gene Expression ClassifierEffective 11/01/2025 - 12/31/2025
-
MOL.TS.260.A: OVA1Effective 11/01/2025 - 12/31/2025
-
MOL.TS.264.A: Select mdxEffective 11/01/2025 - 12/31/2025
-
MOL.TS.266.A: Mitochondrial Disorders Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.267.A: Ehlers-Danlos Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.268.A: Hereditary Connective Tissue Disorder Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.269.A: Autism, Intellectual Disability, and Developmental Delay Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.270.A: ThyroseqEffective 11/01/2025 - 12/31/2025
-
MOL.TS.271.A: PancraGENEffective 11/01/2025 - 12/31/2025
-
MOL.TS.273.A Nonsyndromic Hearing Loss and Deafness Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.276.A: Polymerase Gamma (POLG) Related Disorders Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.282.A: DermTech Pigmented Lesion AssayEffective 11/01/2025 - 12/31/2025
-
MOL.TS.285.A: Multiple Endocrine Neoplasia Type 1 Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.286.A: Multiple Endocrine Neoplasia Type 2 Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.287.A: Hereditary Pancreatitis Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.288.A: Limb-Girdle Muscular Dystrophy Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.290.A: Facioscapulohumeral Muscular Dystrophy Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.294.A: Decipher Prostate Cancer ClassifierEffective 11/01/2025 - 12/31/2025
-
MOL.TS.295.A: Genomic Prostate ScoreEffective 11/01/2025 - 12/31/2025
-
MOL.TS.297.A: ProlarisEffective 11/01/2025 - 12/31/2025
-
MOL.TS.301.A: Neurofibromatosis Type 1 Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.302.A: Legius Syndrome Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.306.A: Genome SequencingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.307.A: AlloSure for Kidney Transplant RejectionEffective 11/01/2025 - 12/31/2025
-
MOL.TS.308.A: Hemoglobinopathies Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.309.A: Friedreich Ataxia Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.310.A: Hereditary Ataxia Multigene Panel TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.311.A: Spinocerebellar Ataxia Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.312.A: Myotonic Dystrophy Type 1 Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.324.A: CHARGE Syndrome and CHD7 Disorder Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.344.A: Chromosomal Microarray for Solid TumorsEffective 11/01/2025 - 12/31/2025
-
MOL.TS.356.A: Microsatellite Instability and Immunohistochemistry Testing in CancerEffective 11/01/2025 - 12/31/2025
-
MOL.TS.359.A: Inflammatory Bowel Disease Biomarker TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.360.A: Inherited Bone Marrow Failure Syndrome (IBMFS) TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.361.A: Human Platelet and Red Blood Cell Antigen GenotypingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.370.A: Inherited Thrombophilia Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.371.A: Noonan Spectrum Disorder Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.396.A: Multi-Cancer Early Detection ScreeningEffective 11/01/2025 - 12/31/2025
-
MOL.TS.401.A: Liver Fibrosis Assessment BiomarkersEffective 11/01/2025 - 12/31/2025
-
MOL.TS.410.A: Cardiomyopathy and Arrhythmia Genetic TestingEffective 11/01/2025 - 12/31/2025
-
MOL.TS.413.A: ColoSense for Colorectal CancerEffective 11/01/2025 - 12/31/2025
-
MOL.TS.419.A: Primary Ciliary Dyskinesia Genetic TestingEffective 11/01/2025 - 12/31/2025